[SCHEDULE 13G/A] Conduit Pharmaceuticals Inc. SEC Filing

Rhea-AI Filing Summary

Sarborg Limited reports a passive 4.0% stake in CDT Equity Inc. The filing, an amendment to Schedule 13G, states Sarborg beneficially owns 123,595 shares of CDT Equity Inc. (ticker CDT). The amount reported reflects a 1-for-15 reverse stock split effected by the issuer on May 15, 2025; share totals were adjusted to give effect to that split.

The filing indicates Sarborg has sole voting and dispositive power over all 123,595 shares and that the position was not acquired to influence control of the company. Ownership is based on 3,065,025 shares outstanding as of August 13, 2025, as confirmed by the issuer.

Positive

• Public disclosure of 4.0% stake increases transparency about major shareholders
• Position reported as passive/non-control under Schedule 13G, reducing immediate governance concerns
• Share totals adjusted for a 1-for-15 reverse split, ensuring reported figures reflect current capitalization

Negative

• None.

Insights

Securities Analyst

TL;DR: Passive 4.0% holding disclosed; position adjusted for a recent reverse split and reported as non-control.

The Schedule 13G/A shows Sarborg Ltd holds 123,595 shares, representing 4.0% of CDT's outstanding common stock after a 1-for-15 reverse split. Filing under Rule 13d-1(b)/(c) signals a passive investor intent rather than an activist or control-seeking stake. Sole voting and dispositive power are reported, but the percentage is below the 5% threshold that typically triggers closer market and regulatory scrutiny. This disclosure improves transparency for market participants regarding shareholder composition.

Corporate Governance Expert

TL;DR: Disclosure is routine and non-disruptive; no governance change implied by this filing.

Sarborg’s certification that the securities were not acquired to influence control and the use of a Schedule 13G amendment are consistent with a passive investment posture. The filing confirms sole control of voting and disposition for the shares, which matters for recordkeeping, but at 4.0% ownership the stake is unlikely to alter governance dynamics or require additional filings absent a change in intent or position size.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

CDT Equity Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

20678X304

(CUSIP Number)

07/08/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 20678X304

1

Names of Reporting Persons

Sarborg Ltd

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 123,595.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 123,595.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

123,595.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.0 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: On May 15, 2025, the Issuer effected a 1-for-15 reverse stock split (the "Reverse Split"). The number of shares of Common Stock reported has been adjusted to give effect to the Reverse Split.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CDT Equity Inc.
(b)	Address of issuer's principal executive offices: 4851 TAMIAMI TRAIL NORTH, SUITE 200, NAPLES, FLORIDA, 34103.
Item 2.
(a)	Name of person filing: Sarborg Limited, a Cayman Islands company (?Sarborg?).
(b)	Address or principal business office or, if none, residence: Willow House, Cricket Square, Grand Cayman, Cayman Islands, KY1-1107.
(c)	Citizenship: Sarborg is a Cayman Islands company.
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 20678X304
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 123,595
(b)	Percent of class: 4.0%, which is based on 3,065,025 shares of common stock, par value $0.0001 per share, of CDT Equity Inc. (formerly known as Conduit Pharmaceuticals Inc., the "Issuer"), issued and outstanding as of August 13, 2025, as independently confirmed by the Issuer.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 123,595
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 123,595
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sarborg Ltd

Signature:	/s/ Mark Taylor
Name/Title:	Executive Director
Date:	08/18/2025

FAQ

What percentage of CDT does Sarborg Ltd own?

Sarborg Ltd beneficially owns 4.0% of CDT Equity Inc., equal to 123,595 shares after adjustment for the reverse split.

Does Sarborg Ltd seek control of CDT (ticker: CDT)?

No. The filing certifies the securities were not acquired to change or influence control and is submitted on Schedule 13G, which is used for passive holdings.

Were the share counts adjusted for corporate actions?

Yes. The filing notes a 1-for-15 reverse stock split effective May 15, 2025, and the reported share count reflects that adjustment.

On what basis is the 4.0% ownership calculated?

The percentage is based on 3,065,025 shares outstanding of CDT as of August 13, 2025, as independently confirmed by the issuer.

Who signed the Schedule 13G/A for Sarborg Ltd?

Mark Taylor, Executive Director, signed the filing dated August 18, 2025.